Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists.
Carbonic anhydrase IX (CAIX) is an antigen ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). The specific and high level of expression in ccRCC makes CAIX an excellent target for imaging ccRCC lesions. We present our experience with immuno–single-photon emission computed tomography (immunoSPECT) imaging with the indium-111 (111In)–labeled anti-CAIX antibody girentuximab in patients presenting with either a primary renal tumor or a history of ccRCC and lesions suspect for metastases during follow-up.
Design, setting, and participants
Twenty-nine patients received 100–200 MBq 111In-labeled girentuximab. Whole-body and single photon emission computed tomography (SPECT) images were acquired after 4–7 d.
Injection with 111In-girentuximab and image acquisition after 4–7 d.
Outcome measurements and statistical analysis
Accuracy of 111In-girentuximab immunoSPECT.
Results and limitations
Distinct uptake of 111In-girentuximab was seen in 16 of 22 patients presenting with a renal mass. All renal masses proven to be ccRCC after resection (n
111In-girentuximab immunoSPECT can be used to detect ccRCC lesions in patients with a primary renal mass and to clarify the nature of lesions suspect for metastases in patients with a history of ccRCC.
Keywords: CAIX, Chimeric monoclonal antibody G250, Clear cell renal cell carcinoma, Girentuximab, Renal masses.
a Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
b Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
© 2013 European Association of Urology, Published by Elsevier B.V.